Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the sale, the director owned 25,545 shares in the company, valued at $639,391.35. This represents a 27.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock traded down $0.97 during midday trading on Monday, hitting $25.03. 1,373,161 shares of the stock were exchanged, compared to its average volume of 2,697,186. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.98. The firm has a market cap of $1.49 billion, a P/E ratio of -13.60 and a beta of 0.41. The company has a 50 day moving average price of $19.07 and a two-hundred day moving average price of $19.95.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. Vestal Point Capital LP boosted its holdings in Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after purchasing an additional 910,000 shares during the period. TCG Crossover Management LLC acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $9,990,000. Duquesne Family Office LLC lifted its position in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at about $8,358,000. Finally, Franklin Resources Inc. grew its position in shares of Enliven Therapeutics by 2,029.3% during the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELVN has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.